DiaMedica director granted 51,189 stock options

DiaMedica Therapeutics Inc. director James T. Parsons received a stock option grant reported on a Form 4.

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. director James T. Parsons received a stock option grant reported on a Form 4. He was awarded options to purchase 51,189 Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036.

The grant is classified as a compensation-related award, not an open-market purchase, and is held directly. According to the disclosure, the options are scheduled to vest in four substantially equal quarterly installments, meaning his ability to exercise them will phase in over time.

Insider Trade Summary

Grant/Award: 51,189 shares

Grant/Award 1 txn

Insider Parsons James T.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	51,189	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 51,189 contracts (Direct)

Footnotes (1)

1. F1. Scheduled to vest in four substantially equal quarterly installments.

Key Figures

Options granted: 51,189 options Exercise price: $5.84 per share Expiration date: June 1, 2036 +3 more

6 metrics

Options granted 51,189 options Stock Option (right to buy) grant to director

Exercise price $5.84 per share Conversion or exercise price of granted options

Expiration date June 1, 2036 Option expiration for this grant

Underlying shares 51,189 Voting Common Shares Shares subject to the stock option grant

Post-transaction derivative holdings 51,189 options Total options held following this transaction

Vesting schedule Four quarterly installments Options vest in four substantially equal quarterly installments

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Voting Common Shares, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Voting Common Shares financial

"underlying_security_title: Voting Common Shares"

vesting financial

"Scheduled to vest in four substantially equal quarterly installments."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DiaMedica Therapeutics (DMAC) report for James T. Parsons?

DiaMedica Therapeutics reported a Form 4 showing director James T. Parsons received a grant of stock options for 51,189 Voting Common Shares at a $5.84 exercise price. These options are compensation-related and not an open-market stock purchase.

How many DiaMedica Therapeutics (DMAC) options were granted to James T. Parsons and at what price?

James T. Parsons was granted stock options for 51,189 DiaMedica Therapeutics Voting Common Shares with an exercise price of $5.84 per share. This award was recorded as a derivative acquisition under transaction code A on the Form 4.

When do James T. Parsons’ DiaMedica Therapeutics (DMAC) options expire and how do they vest?

The options granted to James T. Parsons expire on June 1, 2036 and are scheduled to vest in four substantially equal quarterly installments. This means his exercisable options will increase over four quarters rather than becoming fully exercisable immediately.

Was the DiaMedica Therapeutics (DMAC) Form 4 for James T. Parsons a stock purchase or a grant?

The DiaMedica Therapeutics Form 4 for James T. Parsons reports a grant of stock options, not an open-market stock purchase. The transaction code A identifies it as a grant, award, or other acquisition of derivative securities as part of compensation.

How many DiaMedica Therapeutics (DMAC) derivative securities does James T. Parsons hold after this Form 4 grant?

Following the reported grant, James T. Parsons holds 51,189 stock options related to DiaMedica Therapeutics Voting Common Shares. The Form 4 shows these as directly owned derivative securities with that full amount outstanding after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parsons James T.

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.84	06/01/2026		A		51,189		(1)	06/01/2036	Voting Common Shares	51,189	$0	51,189	D

Explanation of Responses:

1. Scheduled to vest in four substantially equal quarterly installments.

	/s/ Joshua L. Colburn, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)